新華醫療(600587.SH)擬受讓長春博迅9.8%股權
格隆匯3月27日丨新華醫療(600587.SH)公佈,長春博迅成立於2001年7月16日,為公司的控股子公司,其主要業務為醫療器械生產及銷售、售後服務;生物製品(限診斷藥品)銷售;實驗室耗材銷售等。
公司擬以人民幣1350.87萬元的價格受讓陳維佳、馮立崗、楊明、時成波、李德、陳立國、陳向民持有的長春博迅生物技術有限責任公司(“長春博迅”)9.80%股權。
此次股權激勵計劃的制定,對長春博迅2016至2018年的營業收入、淨利潤、在研產品立項、競業禁止等均做了明確規定,通過對長春博迅上述指標的考核,長春博迅較好的完成了公司下達的各項任務,主要體現在:股權激勵計劃要求長春博迅2016年至2018年三年營業收入分別為1.87億元、1.87億元、2億元;淨利潤分別為7040萬元、7180萬元、7540萬元,經考核,長春博迅2016至2018年營業收入實際完成分別為2.01億元、2.29億元、2.61億元;淨利潤分別完成7839.06萬元、8994.21萬元、9600.95萬元。
此次交易是長春博迅股權激勵計劃的一部分,通過股權激勵計劃的實施,提升了長春博迅的管理效率,增強了凝聚力,拓寬了長春博迅的後續發展方向,對長春博迅的持續穩定發展起到了積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.